CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 262 enrolled
Drug / intervention
Respimatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04011735
NCT04011735N/ACompleted

A Real-world Non-interventional Study to Assess Patient Satisfaction With and Preference for Re-usable Respimat Soft Mist Inhaler in Patients With Chronic Obstructive Pulmonary Disease.

Boehringer Ingelheim·observational·Posted Jul 8, 2019·Updated Mar 3, 2021

In Brief

An observational study evaluating Respimat for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 262 participants across 20 sites in 6 countries.

Detailed Summary

The study is to assess patient satisfaction with the inhaler attributes of the re-usable Respimat SMI (Spiriva, Striverdi or Spiolto) in patients with COPD, including patients who are Respimat SMI-experienced and Respimat SMI-naïve. This study also aims to examine patient preference for the re-usable Respimat SMI compared to the disposable Respimat SMI in Respimat SMI-experienced patients switching from a disposable to a re-usable Respimat SMI product at study entry.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Denmark, Finland, Germany, Netherlands, Norway
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJul 8, 2019
Enrollment StartSep 30, 2019
Primary CompletionFeb 13, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.0 years ago

Interventions

Respimatdrug

Soft Mist Inhaler product